Clinical Trials Directory

Trials / Completed

CompletedNCT01132274

Radiation Exposure Reduction in Supraventricular Tachycardia Ablation

Near Zero Fluoroscopic Exposure During Catheter Ablation of Supraventricular Arrhythmias

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
210 (actual)
Sponsor
Catholic University of the Sacred Heart · Academic / Other
Sex
All
Age
14 Years – 50 Years
Healthy volunteers
Not accepted

Summary

Radiofrequency catheter ablation (RFCA) is the mainstay of therapy for supraventricular tachyarrhythmias, providing cure in a high percentage of cases. Conventional ablation techniques require the use of fluoroscopy to place and navigate catheters in the heart, thus exposing patients to ionizing radiations with an additional risk of cancer. The feasibility and safety of a non-fluoroscopic RFCA of a wide range of supraventricular arrhythmias using the EnSite NavX mapping system have been recently reported. The NO-PARTY is a multicenter, randomized-controlled trial designed to test the hypothesis that supraventricular arrhythmias RFCA through the non-fluoroscopic EnSite NavX mapping system results in a clinically significant reduction of the exposure to ionizing radiations compared with conventional ablation techniques. NO-PARTY trial will determine whether supraventricular tachyarrhythmia RFCA through a non-fluoroscopic EnSite NavX mapping system is a suitable and cost-effective approach to achieve a clinically significant reduction of ionizing radiation exposure for both the patient and the operator.

Conditions

Interventions

TypeNameDescription
PROCEDURERadiofrequency catheter ablationConventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
PROCEDURERadiofrequency catheter ablationRadiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.

Timeline

Start date
2009-12-01
Primary completion
2013-03-01
Completion
2013-03-01
First posted
2010-05-28
Last updated
2013-04-15

Locations

6 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT01132274. Inclusion in this directory is not an endorsement.